Development and use of engineered peptide deformylases in chemoenzymatic peptide synthesis
PhD ceremony: Ms. C. di Toma, 12.45 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Development and use of engineered peptide deformylases in chemoenzymatic peptide synthesis
Promotor(s): Prof. D.B. Janssen
Faculty: Mathematics and Natural Sciences
The goal of the research reported in this thesis is to explore the potential of the use of peptide deformylase in chemo-enzymatic peptide synthesis. PDF is suitable for the selective N-terminal deformylation of certain N-formyl-peptides without concurrent peptide bond hydrolysis. The challenge of applying PDF industrially prompted us to focus on the development of a new purification method to remove proteins with peptidase activity from the PDF. The use of enzyme engineering in combination with anion-exchange chromatography was proved to be a cost-efficient and industrially applicable purification method. Other aspects such as improving the stability and modifying the substrate specificity were also investigated. In order to broaden the specificity of PDF, we decided to use saturated mutagenesis at positions that play an important role in substrate recognition. A fast assay for the rapid selection of improved peptide deformylase variants in E. coli colonies was developed to analyze the constructed libraries. Various clones displaying new substrate specificity were recovered, sequenced and partially characterized.
Last modified: | 13 March 2020 01.00 a.m. |
More news
-
03 July 2025
Erik Heeres receives RUG Impact Innovator Excellence Award
During the RUG Ventures Innovation Day, Prof. Erik Heeres of the Faculty of Science and Engineering (RUG) was awarded the Impact Innovator Excellence Award.
-
02 July 2025
Relinde Weil reappointed as a member of the Supervisory Board UG
The Minister of Education has reappointed Relinde Weil for a second term as a member of the Supervisory Board of the University of Groningen.
-
02 July 2025
€ 30 million investment for UG spin-off Portal Biotech
Portal Biotech, a pioneer in nanopore-based protein identification and sequencing technology, has raised € 30 million in Series A funding. The funding will support commercial rollout and team growth.